Ann Dermatol.  2019 Jun;31(3):263-271. 10.5021/ad.2019.31.3.263.

Anti-Wrinkle Efficacy of Cross-Linked Hyaluronic Acid-Based Microneedle Patch with Acetyl Hexapeptide-8 and Epidermal Growth Factor on Korean Skin

• An JH
• Lee HJ
• Yoon MS
• Kim DH

• KMID: 2444857
• DOI: http://doi.org/10.5021/ad.2019.31.3.263

Abstract

BACKGROUND
Hyaluronic acid (HA)-based microneedle patch has recently been studied for wrinkle improvement. Cross-linked HA (CLHA) is widely used in dermal fillers. Acetyl hexapeptide-8 (AHP-8) and epidermal growth factor (EGF) are used for cosmetic ingredients.
OBJECTIVE
This study aimed to verify the efficacy of the CLHA/HA-based patch with microstructure (microneedle patch) containing AHP-8 or EGF.
METHODS
A total of 52 Korean females were enrolled in a double-blind, randomized, controlled, split-face trial. The subjects were divided into 3 groups: (1) microneedle patch alone, (2) microneedle patch/AHP-8, and (3) microneedle patch/EGF. The treatment was applied on the periorbital and nasolabial fold area for 4 hours to completely dissolve the microstructures once per week for 29 days. Evaluations, including photodamage scoring, image analysis with Antera 3D® (Miravex, Ireland), skin hydration measurement, and adverse effect assessments, were performed at each visit.
RESULTS
Fifty subjects (96.2%) completed this clinical study. On day 29 after application, statistically significant improvements in wrinkle and skin hydration were observed in all groups (p<0.01). Treatment with microneedle patch/AHP-8 and microneedle patch/EGF showed statistically significant improvements in wrinkle compared with microneedle patch alone (p<0.05). No serious adverse effects were noted.
CONCLUSION
Combination of CLHA-based microneedle patch and functional cosmetic ingredients can improve wrinkle with minimal discomfort.

Keyword

Acetyl hexapeptide-8; Cross-linked hyaluronic acid; Epidermal growth factor; Hyaluronic acid; Microneedle patch

MeSH Terms

Clinical Study
Dermal Fillers
Epidermal Growth Factor*
Female
Humans
Hyaluronic Acid
Nasolabial Fold
Skin*
Dermal Fillers
Epidermal Growth Factor
Hyaluronic Acid

Figure

• 

  Fig. 1 The image of split-face experiment. Red circle: patch attachment site.

• 

  Fig. 2 (A) Microneedle patch image, (B) microscopic images of microstructures (×20, ×50).

• 

  Fig. 3 (A) Penetrated and dyed microscopic image of porcine skin. (B) Scanning electron microscope images of dissolved microstructures depending on the application time differences (from the left side) 10 seconds, 15 minutes, and 30 minutes, respectively.

• 

  Fig. 4 Mean change in indentation index (medium and large filter) of the Antera 3D® using (A) microneedle patch alone, (B) microneedle patch/acetyl hexapeptide-8 (AHP-8), and (C) microneedle patch/epidermal growth factor (EGF) on the lateral periorbital area.*p<0.05, **p<0.01, ***p<0.001, statistically significant compared with baseline.

• 

  Fig. 5 Mean change in indentation index (medium and large filter) of the Antera 3D® using (A) microneedle patch alone, (B) microneedle patch/acetyl hexapeptide-8 (AHP-8), and (C) microneedle patch/epidermal growth factor (EGF) on the nasolabial folds.*p<0.05, **p<0.01, ***p<0.001, statistically significant compared with baseline.

• 

  Fig. 6 Improvement ratio of indentation index (medium [A] and large [B]) of the Antera 3D® on the lateral periorbital area at day 29 after the first application of microneedle patch, microneedle patch/acetyl hexapeptide-8 (AHP-8), and microneedle patch/epidermal growth factor (EGF). *p<0.05, statistically significant compared with microneedle patches.

• 

  Fig. 7 Photograph and Antera 3D® image of a wrinkle at day 0 and day 29 after treatment of microneedle patch (A), microneedle patch/ acetyl hexapeptide-8 (B), and microneedle patch/epidermal growth factor (C).

Reference

1. Papakonstantinou E, Roth M, Karakiulakis G. Hyaluronic acid: a key molecule in skin aging. Dermatoendocrinol. 2012; 4:253–258.

2. Prestwich GD, Marecak DM, Marecek JF, Vercruysse KP, Ziebell MR. Controlled chemical modification of hyaluronic acid: synthesis, applications, and biodegradation of hydrazide derivatives. J Control Release. 1998; 53:93–103.

3. Bulpitt P, Aeschlimann D. New strategy for chemical modification of hyaluronic acid: preparation of functionalized derivatives and their use in the formation of novel biocompatible hydrogels. J Biomed Mater Res. 1999; 47:152–169.

4. Al-Sibani M, Al-Harrasi A, Neubert RHH. Evaluation of in-vitro degradation rate of hyaluronic acid-based hydrogel cross-linked with 1, 4-butanediol diglycidyl ether (BDDE) using RP-HPLC and UV-Vis spectroscopy. J Drug Deliv Sci Technol. 2015; 29:24–30.

5. Kenne L, Gohil S, Nilsson EM, Karlsson A, Ericsson D, Helander Kenne A, et al. Modification and cross-linking parameters in hyaluronic acid hydrogels--definitions and analytical methods. Carbohydr Polym. 2013; 91:410–418.

6. Liu S, Jin MN, Quan YS, Kamiyama F, Kusamori K, Katsumi H, et al. Transdermal delivery of relatively high molecular weight drugs using novel self-dissolving microneedle arrays fabricated from hyaluronic acid and their characteristics and safety after application to the skin. Eur J Pharm Biopharm. 2014; 86:267–276.

7. Choi SY, Kwon HJ, Ahn GR, Ko EJ, Yoo KH, Kim BJ, et al. Hyaluronic acid microneedle patch for the improvement of crow's feet wrinkles. Dermatol Ther. 2017; 30:e12546.

8. Kim M, Yang H, Kim H, Jung H, Jung H. Novel cosmetic patches for wrinkle improvement: retinyl retinoate- and ascorbic acid-loaded dissolving microneedles. Int J Cosmet Sci. 2014; 36:207–212.

9. Lee C, Yang H, Kim S, Kim M, Kang H, Kim N, et al. Evaluation of the anti-wrinkle effect of an ascorbic acid-loaded dissolving microneedle patch via a double-blind, placebo-controlled clinical study. Int J Cosmet Sci. 2016; 38:375–381.

10. Hong JY, Ko EJ, Choi SY, Li K, Kim AR, Park JO, et al. Efficacy and safety of a novel, soluble microneedle patch for the improvement of facial wrinkle. J Cosmet Dermatol. 2018; 17:235–241.

11. Chung JH, Lee SH, Youn CS, Park BJ, Kim KH, Park KC, et al. Cutaneous photodamage in Koreans: influence of sex, sun exposure, smoking, and skin color. Arch Dermatol. 2001; 137:1043–1051.

12. Larnier C, Ortonne JP, Venot A, Faivre B, Béani JC, Thomas P, et al. Evaluation of cutaneous photodamage using a photographic scale. Br J Dermatol. 1994; 130:167–173.

13. Messaraa C, Metois A, Walsh M, Hurley S, Doyle L, Mansfield A, et al. Wrinkle and roughness measurement by the Antera 3D and its application for evaluation of cosmetic products. Skin Res Technol. 2018; 24:359–366.

14. Hamilton JD. Fabrication and analysis of injection molded plastic microneedle arrays [thesis]. Atlanta: Georgia Institute of Technology;2010.

15. Weindl G, Schaller M, Schäfer-Korting M, Korting HC. Hyaluronic acid in the treatment and prevention of skin diseases: molecular biological, pharmaceutical and clinical aspects. Skin Pharmacol Physiol. 2004; 17:207–213.

16. Tammi MI, Day AJ, Turley EA. Hyaluronan and homeostasis: a balancing act. J Biol Chem. 2002; 277:4581–4584.

17. Wang F, Garza LA, Kang S, Varani J, Orringer JS, Fisher GJ, et al. In vivo stimulation of de novo collagen production caused by cross-linked hyaluronic acid dermal filler injections in photodamaged human skin. Arch Dermatol. 2007; 143:155–163.

18. Shoshani D, Markovitz E, Monstrey SJ, Narins DJ. The modified Fitzpatrick Wrinkle Scale: a clinical validated measurement tool for nasolabial wrinkle severity assessment. Dermatol Surg. 2008; 34:Suppl 1. S85–S91. discussion S91.

19. Linming F, Wei H, Anqi L, Yuanyu C, Heng X, Sushmita P, et al. Comparison of two skin imaging analysis instruments: the VISIA® from Canfield vs the ANTERA 3D® CS from Miravex. Skin Res Technol. 2018; 24:3–8.

20. Blanes-Mira C, Clemente J, Jodas G, Gil A, Fernández-Ballester G, Ponsati B, et al. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002; 24:303–310.

21. Wang Y, Wang M, Xiao S, Pan P, Li P, Huo J. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol. 2013; 14:147–153.

22. Gutierrez LM, Viniegra S, Rueda J, Ferrer-Montiel AV, Canaves JM, Montal M. A peptide that mimics the C-terminal sequence of SNAP-25 inhibits secretory vesicle docking in chromaffin cells. J Biol Chem. 1997; 272:2634–2639.

23. Schouest JM, Luu TK, Moy RL. Improved texture and appearance of human facial skin after daily topical application of barley produced, synthetic, human-like epidermal growth factor (EGF) serum. J Drugs Dermatol. 2012; 11:613–620.

24. An JJ, Eum WS, Kwon HS, Koh JS, Lee SY, Baek JH, et al. Protective effects of skin permeable epidermal and fibroblast growth factor against ultraviolet-induced skin damage and human skin wrinkles. J Cosmet Dermatol. 2013; 12:287–295.

25. Park J, Seo J, Shin JU, Jeong DH, Kim JD, Lee KH. Efficacy of biodegradable microneedle patches on periorbital wrinkles. Korean J Dermatol. 2014; 52:597–607.

26. Park S, Park KY, Yeo IK, Cho SY, Ah YC, Koh HJ, et al. Investigation of the degradation-retarding effect caused by the low swelling capacity of a novel hyaluronic Acid filler developed by solid-phase crosslinking technology. Ann Dermatol. 2014; 26:357–362.

27. Fraser JR, Laurent TC, Laurent UB. Hyaluronan: its nature, distribution, functions and turnover. J Intern Med. 1997; 242:27–33.

28. De Boulle K, Glogau R, Kono T, Nathan M, Tezel A, Roca-Martinez JX, et al. A review of the metabolism of 1,4-butanediol diglycidyl ether-crosslinked hyaluronic acid dermal fillers. Dermatol Surg. 2013; 39:1758–1766.

29. Edsman K, Nord LI, Ohrlund A, Lärkner H, Kenne AH. Gel properties of hyaluronic acid dermal fillers. Dermatol Surg. 2012; 38(7 Pt 2):1170–1179.

30. Kablik J, Monheit GD, Yu L, Chang G, Gershkovich J. Comparative physical properties of hyaluronic acid dermal fillers. Dermatol Surg. 2009; 35:Suppl 1. 302–312.

31. Choi JT, Park SJ, Park JH. Microneedles containing cross-linked hyaluronic acid particulates for control of degradation and swelling behaviour after administration into skin. J Drug Target. 2018; 26:884–894.